These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 16361125
1. MRI and PET in monitoring response in lymphoma. Rahmouni A, Luciani A, Itti E. Cancer Imaging; 2005 Nov 23; 5 Spec No A(Spec No A):S106-12. PubMed ID: 16361125 [Abstract] [Full Text] [Related]
2. PET/CT for therapy response assessment in lymphoma. Hutchings M, Barrington SF. J Nucl Med; 2009 May 23; 50 Suppl 1():21S-30S. PubMed ID: 19380407 [Abstract] [Full Text] [Related]
4. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. Kasamon YL, Jones RJ, Wahl RL. J Nucl Med; 2007 Jan 23; 48 Suppl 1():19S-27S. PubMed ID: 17204717 [Abstract] [Full Text] [Related]
5. [Usefulness of FDG-PET in monitoring effects of the modality therapy for central nervous system malignant lymphoma: report of three cases]. Masada T, Matsumoto Y, Kawai N, Tamiya T, Nagao S. No Shinkei Geka; 2004 Aug 23; 32(8):859-64. PubMed ID: 15478653 [Abstract] [Full Text] [Related]
7. Impact of FDG-PET/CT in the management of lymphoma. Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Ann Nucl Med; 2011 Dec 23; 25(10):701-16. PubMed ID: 22037934 [Abstract] [Full Text] [Related]
8. Positron emission tomography/computed tomography: the current technology and applications. Mittra E, Quon A. Radiol Clin North Am; 2009 Jan 23; 47(1):147-60. PubMed ID: 19195540 [Abstract] [Full Text] [Related]
9. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F, Catalano L, Liuzzi R, Rotoli B, Del Vecchio S, Pace L, Salvatore M. J Nucl Med; 2008 Feb 23; 49(2):195-200. PubMed ID: 18199607 [Abstract] [Full Text] [Related]
11. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Ribrag V, Vanel D, Leboulleux S, Lumbroso J, Couanet D, Bonniaud G, Aupérin A, Masson F, Bosq J, Edeline V, Fermé C, Pigneur F, Schlumberger M. Eur J Radiol; 2008 May 23; 66(2):325-31. PubMed ID: 17651934 [Abstract] [Full Text] [Related]
12. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience. Coha B, Radmilović K, Gardasanić J, Daković M, Stefanić M, Latić A, Mitrecić D. Acta Clin Croat; 2009 Mar 23; 48(1):35-9. PubMed ID: 19623870 [Abstract] [Full Text] [Related]
16. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Karantanis D, O'Neill BP, Subramaniam RM, Peller PJ, Witte RJ, Mullan BP, Wiseman GA. Clin Nucl Med; 2007 Apr 23; 32(4):271-4. PubMed ID: 17413571 [Abstract] [Full Text] [Related]
17. PET monitoring of therapy response in head and neck squamous cell carcinoma. Schöder H, Fury M, Lee N, Kraus D. J Nucl Med; 2009 May 23; 50 Suppl 1():74S-88S. PubMed ID: 19380408 [Abstract] [Full Text] [Related]
18. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Metser U, Even-Sapir E. Semin Nucl Med; 2007 May 23; 37(3):206-22. PubMed ID: 17418153 [Abstract] [Full Text] [Related]